CR Double-Crane(SH:600062) Zheng Quan Zhi Xing·2025-07-24 16:21Core Viewpoint - The announcement highlights that China Resources Double Crane Pharmaceutical Co., Ltd.'s wholly-owned subsidiary, Double Crane Limin Pharmaceutical (Jinan) Co., Ltd., has successfully passed the GMP compliance inspection, which is crucial for maintaining product quality and production capacity in the pharmaceutical market [1][6]. Group 1: GMP Inspection Information - The GMP compliance inspection was conducted from April 22 to April 25, 2025, at the new solid preparation workshop for tablet and hard capsule production [1]. - The investment for the new solid preparation workshop was approximately RMB 260 million (unaudited) [1]. Group 2: Product and Market Overview - The solid preparation workshop produces two key products: Nifedipine controlled-release tablets and Levofloxacin hydrochloride capsules [2][3]. - Nifedipine controlled-release tablets have a projected sales revenue of RMB 147 million for 2024, with a market share of 3.10% for Double Crane Limin among 28 approved manufacturers in China [5][6]. - Levofloxacin hydrochloride capsules are part of a competitive market with 62 approved manufacturers, and the total sales for 2024 are estimated at RMB 392 million [6]. Group 3: Impact on the Company - The successful GMP compliance inspection is expected to enhance the company's ability to maintain stable product quality and production capacity, thereby meeting market demand [6]. - The inspection results are not anticipated to have a significant impact on the company's overall performance [6].